tbuckley/cabot-search huggingface dataset:
Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.
Authors: Ozan Unlu, Sevda Aygun, Hilbrahim Petekkaya, Gizem Gecmez, Emir C. Roach, Taner Babacan, Ugur Sahin, Özge Keskin, Neyran Kertmen, Sercan Aksoy, Kadri Altundag
Journal: Journal of Clinical Oncology (2013)

e11544 Background: Identification of simple and measurable prognostic factors is an important issue in treatment evaluation of breast cancer. Although various markers are considered while making a decision to treatment modality, clinicians investigate for new prognostic factors for reason of highly variable responses of individuals. Therefore, this study estimates the survival probability of the neutrophil to lymphocyte ratio (NLR) for patients with metastatic breast cancer. Methods: We included the patients with metastatic breast carcinoma who were treated for metastasis. NLR were calculated and patients were divided into four quartiles (25th, 50th and 75th NLR; the lowest being the 1st quartile, the highest being 4th quartile ). Survival status was retrieved from our cancer registry. Survival analysis, stratified by NLR quartiles, was used to evaluate the predictive value of NLR. Results: Eighty-one patients with metastatic breast cancer were included in this study. Median age of diagnosis of the patients was 47 (26-83), the majority of them had grade II (%37) and grade III (%29.6) tumors and were metastatic at the time of their initial diagnosis. ER (+), PR (+) and HER2 (+) percentages were confirmed as 82%, 73% and 24% ,respectively. Ten percent of the patients were triple negative. Median follow-up time was 26 months and 29 patients died during the follow up period. We analyzed the overall survival among NLR quartiles. When we compared the quartiles with the highest and lowest NLR values, the quartile with the lowest NLR values had longer median overall survival than the quartile with the highest NLR values (212 vs. 27 months; p=0.01). The second and third quartiles, however, showed no statistically significant difference of overall survival between four quartiles. Conclusions: NLR can be a prognostic factor for overall survival in metastatic breast cancer patients.
Low-Dose Cytosine Arabinoside Therapy for Neonates with Down Syndrome (DS) and Transient Leukemia (TL).
Authors: Hideki Muramatsu, Yasuhide Hayashi, Machiko Kawamura, Seiji Kojima, Miharu Yabe, Keiichi Isoyama, Tomohiko Taki, Kohichiro Tsuji, Masahiro Tsuchida, Atsushi Manabe, Etsuro Ito, Shotaro Iwamoto, Hiromi Kato, Aiko Sumie, Takashi Taga, Keiko Nomura, Daisuke Hasegawa, Ken-ichiro Watanabe, Akira Kikuchi
Journal: Blood (2010)
P1-173: Pulmonary Neuroendocrine (NE) tumors: a 15-year retrospective clinicopathologic study of 317 cases
Authors: MS Roh, L Krug, M Kris, Vl Rusch, Mf Zakowski, Al Moreira, Ds Klimstra, W Gerald, Wd Travis
Journal: Journal of Thoracic Oncology (2007)
Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype
Authors: Xianli Shen, Miguel A Burguillos, Ahmed M Osman, Jeroen Frijhoff, Alejandro Carrillo-Jiménez, Sachie Kanatani, Martin Augsten, Dalel Saidi, Johanna Rodhe, Edel Kavanagh, Anthony Rongvaux, Vilma Rraklli, Ulrika Nyman, Johan Holmberg, Arne Östman, Richard A Flavell, Antonio Barragan, Jose Luis Venero, Klas Blomgren, Bertrand Joseph
Journal: Nature Immunology (2016)
Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR).
Authors: Florence Joulain, Eric Van Cutsem, Sheikh Usman Iqbal, Martin Hoyle, Carmen Joseph Allegra
Journal: Journal of Clinical Oncology (2012)

3602 Background: VELOUR evaluated the efficacy and safety of the novel fusion protein aflibercept (VEGF Trap) in combination with FOLFIRI in mCRC patients previously treated with oxaliplatin. Median OS showed significant improvement with 12.06 months in placebo arm vs 13.50 months in aflibercept arm (p=0.0032; HR=0.82 [95.34% CI: 0.71 to 0.94]) [Van Cutsem, 2011]. Since survival data in oncology are usually right skewed, median survival is preferred for regulatory purposes. However, mean survival estimation can render a more meaningful estimate for long term benefit of interventions, and be effectively applied to clinical and economic decision support. Estimating mean OS also allows payers to derive an estimation of total costs and outcomes in the population. The purpose of this study was to estimate the mean OS for VELOUR trial. Methods: During the trial follow-up period, mean OS is not observable and can be estimated by extrapolating the trial Kaplan-Meier curve using a survival function. Several standard parametric distributions were tested: exponential, weibull, lognormal, loglogistic and gompertz. Akaike’s Information Criteria (AIC), Bayesian Information Criteria (BIC) and graphical method were used to evaluate the goodness of fit of the distributions. Models were run by treatment arm separately or combining the two arms and using treatment as covariate to control for variation. Results: Using AIC/BIC and graphical method, loglogistic function best fit the VELOUR data both with and without treatment as covariate. Weibull distribution is used for sensitivity analysis. Conclusions: Using loglogistic function, mean OS benefit for aflibercept in combination with FOLFIRI is at least 2.9 months (versus 1.4 months difference in median survival). The results have important implications for clinical and economic decision support. Study NCT00561470 was funded by sanofi, in partnership with Regeneron. [Table: see text]
Living kidney donation
Authors: Pippa Bailey, Anusha Edwards, Aisling E Courtney
Journal: BMJ (2016)

#### What you need to know Globally each year more than 30 000 people become living kidney donors.1 In the UK there have been more than 1000 living kidney donations every year since 2009.2 There are two types of kidney donation, living and deceased. Living donor kidney transplantation offers the best treatment in terms of life expectancy and quality of life 2 3 4 5 6 7 8 9 for most people with kidney failure (see box 1), the prevalence of which is steadily rising. Living kidney donation is constantly evolving, with new ways of maximising recipient opportunities and increasing information regarding long term outcomes associated with donation. This review presents an overview of current practice covering who can donate, to whom, and the possible impact of donation on the donor’s health. #### Box 1: Advantages of living donor over deceased donor kidney transplants
Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.
Authors: Rodger E. Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, Hongwei Yin, Quick Que, David Azorsa, Louise M. Perkins, Esteban Braggio, Craig B. Reeder, Rafael Fonseca, P. Leif Bergsagel, Spyro Mousses, A. Keith Stewart
Journal: Blood (2009)
Pancreatic Safety of Sitagliptin in the TECOS Study
Authors: John B. Buse, M. Angelyn Bethel, Jennifer B. Green, Susanna R. Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, Tsvetalina Tankova, Julio Wainstein, Robert Josse, John M. Lachin, Samuel S. Engel, Keyur Patel, Eric D. Peterson, Rury R. Holman
Journal: Diabetes Care (2016)

We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and pancreatic cancer were collected prospectively for 14,671 participants during a median follow-up time of 3 years, and were adjudicated blindly.Baseline differences were minimal between participants confirmed to have no pancreatic events, acute pancreatitis, or pancreatic cancer. Among those participants randomized to receive sitagliptin, 23 (0.3%) (vs. 12 randomized to receive placebo [0.2%]) had pancreatitis (hazard ratio 1.93 [95% CI 0.96-3.88], P = 0.065; 0.107 vs. 0.056/100 patient-years), with 25 versus 17 events, respectively. Severe pancreatitis (two fatal) occurred in four individuals allocated to receive sitagliptin. Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28-1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years). Meta-analysis with two other DPP-4i cardiovascular outcome studies showed an increased risk for acute pancreatitis (risk ratio 1.78 [95% CI 1.13-2.81], P = 0.01) and no significant effect for pancreatic cancer (risk ratio 0.54 [95% CI 0.28-1.04], P = 0.07).Pancreatitis and pancreatic cancer were uncommon events with rates that were not statistically significantly different between the sitagliptin and placebo groups, although numerically more sitagliptin participants developed pancreatitis and fewer developed pancreatic cancer. Meta-analysis suggests a small absolute increased risk for pancreatitis with DPP-4i therapy.
Development of peptide inhibitors of HIV transmission
Authors: Siyu Shi, Peter K. Nguyen, Henry J. Cabral, Ramon Diez-Barroso, Paul J. Derry, Satoko M. Kanahara, Vivek A. Kumar
Journal: Bioactive Materials (2016)

Treatment of HIV has long faced the challenge of high mutation rates leading to rapid development of resistance, with ongoing need to develop new methods to effectively fight the infection. Traditionally, early HIV medications were designed to inhibit RNA replication and protein production through small molecular drugs. Peptide based therapeutics are a versatile, promising field in HIV therapy, which continues to develop as we expand our understanding of key protein-protein interactions that occur in HIV replication and infection. This review begins with an introduction to HIV, followed by the biological basis of disease, current clinical management of the disease, therapeutics on the market, and finally potential avenues for improved drug development.
Response to: World Rugby’s erroneous and misleading representation of Australian sports’ injury statistics
Authors: Martin Raftery
Journal: British Journal of Sports Medicine (2016)

As chief executive officer of World Rugby I would like to respond to Piggin and Pollock regarding their editorial titled ‘World Rugby's Erroneous and Misleading Representation of Australian Sports’ Injury Statistics’.

World Rugby acknowledges that errors were made in the development of marketing and …
P1-240: OASIS, a prospective observation study of treatment of chemotherapy-induced anaemia with every 3 weeks Darbepoetin alfa
Authors: Karin E. Pat, Beatrijs Anrys, D Verhulst, F Van Aelst, K Eygen, D Galdermans, D Verhoeven, M Polus, K Seegers, Md Derde, J Vansteenkiste
Journal: Journal of Thoracic Oncology (2007)
Anti-VEGF treatments in epithelial ovarian cancer: Is it only anti-angiogenesis?
Authors: X. Trinh, W. A. Tjalma, L. Y. Dirix, P. B. Vermeulen, G. G. Van den Eynden, S. J. Van Laere, I. Van Der Auwera, P. A. van Dam
Journal: Journal of Clinical Oncology (2008)

14548 Background: VEGF-A and angiogenesis are important targets in ovarian cancer because bevacizumab or VEGF-TRAP as a single agent induces encouraging responses in refractory patients. pVEGFR2 has been shown to be a biomarker for bevacizumab treatment in inflammatory breast cancer patients. The object of this study was to study the presence of a correlation between the Akt/mTOR/p70S6K1 (Amp) pathway and the VEGF-A pathway. pS6 and p4EBP1 are downstream targets and presumed to be representative for the activation of Amp pathway. Methods: Epithelial ovarian cancer FFPE material was collected in a tissue micro array. Immunohistochemistry was performed using pS6, p4EBP1 and pVEGFR2. An H-score was used to quantify the staining. Results: Patients (n=89) were FIGO stage I in 21%, stage II in 4%, stage III in 62% and 11% stage IV. Considering both primary as well as metastatic lesions together, pVEGFR2 was correlated with p4EBP1 (Spearman=0.174; p=0.008). More profound correlation was found between pS6 and pVEGFR2. (r=0.333; p<0.0001). The correlation of pS6 and pVEGFR2 was present in tissue of primary tumors (r=0.279; p=0.002) but was more pronounced in tissue of metastatic lesions. (r=0.444; p<0.0001). In patients who received uniform first line combination taxane-platinum based chemotherapy, a co-expression of pS6 and pVEGFR2 on tumor cells was associated with reduced overall survival (RR 3.05 95%CI [1.11–8.42] p=0.031) in a multivariate Cox regression model. Conclusions: A correlation was found between markers of the Amp pathway and pVEGFR2. A very plausible explanation for the found correlation is that VEGF-A is able to activate VEGFR2/AKT/mTOR/p70S6K1 in tumor cells similar to endothelial cells. This suggest that VEGF-A might be a key-stimulating growth factor to the tumor cells itself by influencing downstream cell signaling proteins. The anti-tumoral activity of anti-VEGF treatments could thus be explained by reducing an important tumor cell growth factor besides anti-angiogenesis. Reduced survival in patients with a presumed activated pathway indicate that this pathway is potentially a biological important mechanism in ovarian cancer. No significant financial relationships to disclose.
P2-191: Efficacy of perioperative chemotherapy with advanced non-small-cell lung cancer
Authors: Sun-Young Kim, Choon Hee Son, Jung-Sun Yoo, Mi-Kyong Joung, Yu-Jin Lee, Jeong Eun Lee, Hee Sun Park, Sung Soo Jung, Ju-Ock Kim
Journal: Journal of Thoracic Oncology (2007)
Appropriate Use of Antiemetics to Prevent Chemotherapy-Induced Nausea and Vomiting
Authors: Devon K. Check, Ethan M. Basch
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P1-113: Malignant Pleural Mesothelioma (MPM): our experience with 91 patients
Authors: Sara Cingarlini, Giovenzio Genestreti, Alberto Terzi, Maria Bonomi, Gianluca Fogazzi, Alberto Ravaioli, Maximiliam Papi, Annamaria Molino, Gianluigi Cetto, Antonio Santo
Journal: Journal of Thoracic Oncology (2007)
P1-123: Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients.
Authors: Joël Guigay, Pierre Ruffié, Sophie Leboulleux, Dominique Elias, Thierry De Baere, Clarisse Dromain, Pierre Duvillard, Michel Ducreux, Martin Schlumberger, Eric Baudin
Journal: Journal of Thoracic Oncology (2007)
P3-042: Image-Guided Radiation Therapy for Stereotactic Radiosurgery in Lung Tumor
Authors: Wonsik Choi, Eun Kyung Choi, Jung Shin Lee, Seung Do Ahn, Seong Soo Shin, Si Yeol Song, Jihoon Cheung, Yeon-Mok Oh, Dong-Kwan Kim, Joon Beom Seo
Journal: Journal of Thoracic Oncology (2007)
Hyperthermia for Major Depressive Disorder?—Reply
Authors: Charles L. Raison, Clemens W. Janssen, Christopher A. Lowry
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Ultrastrong trapping of VEGF by graphene oxide: Anti-angiogenesis application
Authors: Pei-Xin Lai, Chung-Wein Chen, Shih-Chun Wei, Tzu-Yu Lin, Hong-Jyuan Jian, Irving Po-Jung Lai, Ju-Yi Mao, Pang-Hung Hsu, Han-Jia Lin, Wen-Shyong Tzou, Shiow-Yi Chen, Scott G. Harroun, Jui-Yang Lai, Chih-Ching Huang
Journal: Biomaterials (2016)
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002
Authors: Takashi Ishida, Hiroshi Fujiwara, Kisato Nosaka, Naoya Taira, Yasunobu Abe, Yoshitaka Imaizumi, Yukiyoshi Moriuchi, Tatsuro Jo, Kenichi Ishizawa, Kensei Tobinai, Kunihiro Tsukasaki, Shigeki Ito, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, Shuichi Midorikawa, Wanda Ruiz, Tomoko Ohtsu
Journal: Journal of Clinical Oncology (2016)

Purpose Few treatment options exist for adult T-cell leukemia/lymphoma (ATL), and the prognosis for this disease is poor. A phase I study of lenalidomide demonstrated preliminary antitumor activity in patients with relapsed ATL. The current phase II study evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed or recurrent ATL. Patients and Methods Patients 20 years of age or older with acute, lymphoma, or unfavorable chronic subtype ATL, who had received one or more prior anti-ATL systemic chemotherapy and achieved stable disease or better on their last anti-ATL therapy with subsequent relapse or recurrence, were eligible. Patients received oral lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity. The primary end point was overall response rate; secondary end points included safety, tumor control rate (stable disease or better), time to response, duration of response, time to progression, progression-free survival, and overall survival. Results Objective responses were noted in 11 of 26 patients (overall response rate, 42%; 95% CI, 23% to 63%), including four complete responses and one unconfirmed complete response. The tumor control rate was 73%. The median time to response and duration of response were 1.9 months and not estimable, respectively, and the median time to progression was 3.8 months. The median progression-free survival and overall survival were 3.8 and 20.3 months, respectively. The most frequent grade ≥ 3 adverse events were neutropenia (65%), leukopenia (38%), lymphopenia (38%), and thrombocytopenia (23%), which were all manageable and reversible. Conclusion Lenalidomide demonstrated clinically meaningful antitumor activity and an acceptable toxicity profile in patients with relapsed or recurrent aggressive ATL, hinting at its potential to become a treatment option. Further investigations of lenalidomide in ATL and other mature T-cell neoplasms are warranted.
<i>BRCA1</i>-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Authors: Esther H. Lips, Rashmie D. Debipersad, Caroline E. Scheerman, Lennart Mulder, Gabe S. Sonke, Lizet E. van der Kolk, Jelle Wesseling, Frans B.L. Hogervorst, Petra M. Nederlof
Journal: Clinical Cancer Research (2016)

Purpose: As estrogen receptor-positive (ER+) breast cancer in BRCA1 mutation carriers arises at an older age with less aggressive tumor characteristics than ER-negative (ER-) BRCA1-mutated breast cancer, it has been suggested that these tumors are "sporadic" and not BRCA1 driven. With the introduction of targeted treatments specific for tumors with a nonfunctioning BRCA1 or BRCA2 gene, the question whether the BRCA genes are impaired in the tumor is highly relevant. Therefore, we performed genomic profiling of BRCA1-mutated ER+ tumors.Experimental Design: Genomic profiling, BRCA1 promoter methylation assessment, and loss of heterozygosity analysis were done on 16 BRCA1-mutated ER+ tumors. Results were compared with 57 BRCA1-mutated ER- tumors, 36 BRCA2-mutated ER+-associated tumors, and 182 sporadic ER+ tumors.Results: The genomic profile of BRCA1-mutated ER+ tumors was different from BRCA1-mutated ER- breast tumors, but highly similar to BRCA2-mutated ER+ tumors. In 83% of the BRCA1-mutated ER+ tumors, loss of the wild-type BRCA1 allele was observed. In addition, clinicopathologic variables in BRCA1-mutated ER+ cancer were also more similar to BRCA2-mutated ER+ and sporadic ER+ breast cancer than to BRCA1-mutated ER- cancers.Conclusions: As BRCA1-mutated ER+ tumors show a BRCAness copy number profile and LOH, it is likely that the loss of a functional BRCA1 protein plays a role in tumorigenesis in BRCA1-mutated ER+ tumors. Therefore, we hypothesize that these tumors are sensitive to drugs targeting the BRCA1 gene defect, providing new targeted treatment modalities for advanced BRCA-deficient, ER+ breast cancer. Clin Cancer Res; 23(5); 1236-41. ©2016 AACR.
Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer
Authors: Ben Yue, Donglan Cai, Chenchen Liu, Changyi Fang, Dongwang Yan
Journal: Molecular Therapy (2016)

Long noncoding RNAs act as crucial regulators in plenty of human cancers, yet their potential roles and molecular mechanisms in chemoresistance are poorly understood. This study showed that a novel lncRNA, long intergenic noncoding RNA 152 (Linc00152 ), promoted tumor progression and conferred resistance to oxaliplatin (L-OHP)-induced apoptosis in vitro and in vivo. It antagonized chemosensitivity through acting as a competing endogenous RNA to modulate the expression of miR-193a-3p, and then erb-b2 receptor tyrosine kinase 4 (ERBB4). Knockdown of ERBB4 in colon cancer cells decreased AKT phosphorylation, which resulted in decreased L-OHP resistance. Consistent with above findings, the specific AKT signaling inhibitor and activator were used, respectively, which demonstrated that Linc00152 contributed to L-OHP resistance at least partly through activating AKT pathway. Further studies indicated that Linc00152 was increased and appeared to be an independent prognostic factor for decreased survival and increased disease recurrence in stage II and III colon cancer patients undergoing L-OHP-based chemotherapy after surgery. Collectively, our findings established Linc00152 as a candidate prognostic indicator of outcome and drug responsiveness in colon cancer patients, and the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance.